TABLE 3.
Correlation of IL-6R expression with clinicopathological characteristics of CCA patients with gemcitabine response from HDRA results.
| Factors | No. of patients (n = 40) | IL-6R expression | ||
|---|---|---|---|---|
| Low | High | p-value | ||
| Gemcitabine | ||||
| Response or non-response | 8 | 7 | 1 | |
| Response | 5 | 2 | 3 | |
| Non-response | 27 | 8 | 19 | 0.014* |
| Sex | ||||
| Female | 17 | 8 | 9 | |
| Male | 23 | 9 | 14 | 0.429 |
| Age | ||||
| <61 | 16 | 7 | 9 | |
| ≥61 | 17 | 8 | 9 | |
| N/A | 7 | 2 | 5 | 0.701 |
| Histological types | ||||
| Papillary | 12 | 7 | 5 | |
| Non-papillary | 19 | 7 | 12 | |
| N/A | 9 | 3 | 6 | 0.409 |
| Tumor site | ||||
| Intrahepatic | 20 | 9 | 11 | |
| Extrahepatic | 11 | 5 | 6 | |
| N/A | 9 | 3 | 6 | 0.819 |
| Tumor morphology | ||||
| Mass forming | 7 | 3 | 4 | |
| Intraductal growth | 5 | 2 | 3 | |
| Mixed | 19 | 9 | 10 | |
| N/A | 9 | 3 | 6 | 0.917 |
Correlation between IHC, staining score of IL-6R, and clinicopathological features by Fisher’s exact test. *p-values less than 0.05 were considered as a statistical significance.